Yarema Roman, Fetsych Taras, Volodko Natalya, Оhorchak Myron, Petronchak Orest, Huley Roman, Mylyan Yuriy, Glehen Olivier
Department of Oncology and Medical Radiology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
Lviv State Oncological Regional Treatment, Diagnostic Center, Lviv, Ukraine.
J Surg Oncol. 2018 Jun;117(8):1806-1812. doi: 10.1002/jso.25087. Epub 2018 May 14.
Clinical experience suggests that cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) play an important role in the management of ovarian cancer. In order to improve patient selection, the peritoneal surface disease severity score (PSDSS) was previously introduced for use in colorectal cancer patients. However, almost no data exist regarding the utility of the PSDSS index in ovarian cancer patients.
A retrospective study of the effectiveness of CRS and HIPEC was carried out in 59 patients with ovarian cancer. The PSDSS was based on three criteria: symptoms, extent of peritoneal dissemination, and primary tumor structure as assessed by histology and biomarker expression.
The overall survival time for patients with ovarian cancer in PSDSS Stage I was 48 ± 25.3 months. For PSDSS Stage II, the survival time was 26.5 ± 4.7 months. For PSDSS Stage III, it was 15.5 ± 4 months, and for PSDSS Stage IV, it was 6 ± 4.3 months. A multivariate analysis showed that the PSDSS stage was the only independent survival predictor.
These data demonstrate that a PSDSS based on two pathogenetic types may be useful for predicting survival outcomes in ovarian cancer patients treated with CRS/HIPEC.
临床经验表明，细胞减灭术（CRS）和腹腔热灌注化疗（HIPEC）在卵巢癌的治疗中发挥着重要作用。为了改善患者的选择，先前引入了腹膜表面疾病严重程度评分（PSDSS）用于结直肠癌患者。然而，关于PSDSS指数在卵巢癌患者中的效用几乎没有数据。
对59例卵巢癌患者进行了CRS和HIPEC有效性的回顾性研究。PSDSS基于三个标准：症状、腹膜播散范围以及通过组织学和生物标志物表达评估的原发肿瘤结构。
PSDSS I期卵巢癌患者的总生存时间为48±25.3个月。PSDSS II期患者的生存时间为26.5±4.7个月。PSDSS III期为15.5±4个月，PSDSS IV期为6±4.3个月。多因素分析表明，PSDSS分期是唯一的独立生存预测因素。
这些数据表明，基于两种致病类型的PSDSS可能有助于预测接受CRS/HIPEC治疗的卵巢癌患者的生存结果。
